500 J. Fernández-Ruiz and S. González
glutamate. This provides the basis for the development of novel pharmacother-
apies with compounds selective for the different target proteins that form the
endocannabinoid system. However, only a few studies have examined, hitherto,
the potential contribution these compounds might make to the management of
motor disorders in the clinic. The importance of this novel system demands fur-
ther investigation and the development of novel promising compounds for the
symptomatic and/or neuroprotectant treatment of basal ganglia pathology.
Acknowledgements.
StudiesincludedinthisreviewhavebeenmadepossiblebygrantsfromCAM-PRI(08.5/0029/
98 and 08.5/0063/2001) and MCYT (SAF2003-08269).
References
Alexi T, Hughes PE, Faull RLM, Williams LE (1998) 3-Nitropropionic acid’s lethal triplet:
cooperative pathways of neurodegeneration. Neuroreport 9:57–64
Anderson LA, Anderson JJ, Chase TN, Walters JR (1995) The cannabinoid agonists WIN55,
212-2 and CP55,940 attenuate rotational behaviour induced by a dopamine D1 but
not D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res
691:106–114
Aroyo I, González S, Nuñez E, Lastres-Becker I, Sagredo O, Mechoulam R, Romero J,
Ramos JA, Brouillet E, Fernández-Ruiz J (2005) Involvement of CB2 receptors in the
neuroprotective effects of cannabinoids in rats with striatal atrophy induced by local
application of malonate, an experimental model of Huntington’s disease. J Neurosci
(submitted)
Baker D, Pryce G (2003) The therapeutic potential of cannabis in multiple sclerosis. Expert
Opin Investig Drugs 12:561–567
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000)
Cannabinoidscontrolspasticityandtremorinamultiplesclerosismodel.Nature404:84–
87
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Lay-
ward L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in
a multiple sclerosis model. FASEB J 15:300–302
BeltramoM,RodríguezdeFonsecaF,NavarroM,CalignanoA,GorritiMA,Grammatikopou-
los G, Sadile AG, Giuffrida A, Piomelli D (2000) Reversal of dopamine D2 receptor
responses by an anandamide transport inhibitor. J Neurosci 20:3401–3407
BenitoC,NunezE,TolonRM,CarrierEJ,RabanoA,HillardCJ,RomeroJ(2003)Cannabinoid
CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic
plaque-associated glia in Alzheimer’s disease brains. J Neurosci 23:11136–11141
Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, van Dijk JG, Topper R,
SchwarzM,RoosRA(1999)PathophysiologyofchoreaandbradykinesiainHuntington’s
disease. Mov Disord 14:398–403
Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A, Fernández-
Ruiz J (2001) Changes in cannabinoid CB1 receptors in striatal and cortical regions of
rats with experimental allergicencephalomyelitis,an animal model of multiple sclerosis.
Synapse 41:195–202
Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernández-Ruiz JJ, Di Marzo
V (1999) Brain regional distribution of endocannabinoids: implications for their biosyn-
thesis and biological function. Biochem Biophys Res Commun 256:377–380
Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes in the basal
ganglia circuitry in Parkinson’s disease. Prog Neurobiol 62:63–88